Cross above 200 day moving average, cup and handleGALT cross above 200 day moving average after a lengthy period of consolidation in tightening trading range.
Cup and handle.
Leading drug in a pivotal clinical trial for advanced cirrhosis.
High insider ownership of shares
Recent hiring of a renowned liver expert VP from big pharma
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.76 USD
−47.05 M USD
0.00 USD
43.62 M
About Galectin Therapeutics Inc.
Sector
Industry
CEO
Joel Lewis
Website
Headquarters
Norcross
Founded
2000
FIGI
BBG000BK6FP5
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
Can GALT Vault Back Above The 200?Looks like GALT is back hanging out around the 786 level again. This is where it was trading around before the last big spike. But there's also another level to keep track of which is the 200DMA. Now that GALT is below this level, the 200 might be another possible area of resistance. Given the pos
Bullish Reversal after Options Expiration Today for GALTGALT reported positive results for cancer immunotherapy one week ago. This was followed by algorithm trading taking the stock price lower. There is high open interest on $3, $4, and $5 calls expiring today. The price should reverse and move higher with the expiration of these calls, since the opt
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of GALT is 1.38 USD — it has increased by 0.73% in the past 24 hours. Watch Galectin Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Galectin Therapeutics Inc. stocks are traded under the ticker GALT.
GALT stock has risen by 4.55% compared to the previous week, the month change is a −12.66% fall, over the last year Galectin Therapeutics Inc. has showed a −59.41% decrease.
GALT reached its all-time high on Sep 12, 2003 with the price of 38.28 USD, and its all-time low was 0.30 USD and was reached on Jan 12, 2009. View more price dynamics on GALT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GALT stock is 9.02% volatile and has beta coefficient of 1.89. Track Galectin Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Galectin Therapeutics Inc. there?
Today Galectin Therapeutics Inc. has the market capitalization of 87.19 M, it has decreased by −1.47% over the last week.
Yes, you can track Galectin Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Galectin Therapeutics Inc. is going to release the next earnings report on May 19, 2025. Keep track of upcoming events with our Earnings Calendar.
GALT earnings for the last quarter are −0.19 USD per share, whereas the estimation was −0.16 USD resulting in a −18.75% surprise. The estimated earnings for the next quarter are −0.20 USD per share. See more details about Galectin Therapeutics Inc. earnings.
GALT net income for the last quarter is −11.97 M USD, while the quarter before that showed −11.22 M USD of net income which accounts for −6.66% change. Track more Galectin Therapeutics Inc. financial stats to get the full picture.
No, GALT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 19, 2025, the company has 15 employees. See our rating of the largest employees — is Galectin Therapeutics Inc. on this list?
Like other stocks, GALT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Galectin Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Galectin Therapeutics Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Galectin Therapeutics Inc. stock shows the sell signal. See more of Galectin Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.